US2022241385A1PendingUtilityA1

Diffusion enhancing compounds and their use alone or with thrombolytics

71
Assignee: GAINER JOHN LPriority: Jun 22, 2009Filed: Oct 11, 2021Published: Aug 4, 2022
Est. expiryJun 22, 2029(~2.9 yrs left)· nominal 20-yr term from priority
Inventors:John L. Gainer
A61K 38/482A61K 31/225A61K 47/40A61K 31/203A61P 9/10A61K 9/0019
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A method of treating a mammal having a myocardial infarction, pulmonary embolism, or deep vein thrombosis, wherein the method comprises:
 i) administering a diffusion enhancing compound to said mammal, and   ii) administering a thrombolytic agent to said mammal.   
     
     
         3 - 6 . (canceled) 
     
     
         7 . A method of treating a mammal having a cerebral edema, wherein the method comprises administering a diffusion enhancing compound to said mammal. 
     
     
         8 . A method of treating a mammal having a TIA, wherein the method comprises administering a diffusion enhancing compound to said mammal. 
     
     
         9 . A method as in  claim 2 , wherein said diffusion enhancing compound is a bipolar trans carotenoid. 
     
     
         10 . A method as in  claim 2 , wherein said diffusion enhancing compound is a bipolar trans carotenoid salt. 
     
     
         11 . A method as in  claim 10 , wherein said bipolar trans carotenoid salt is formulated with a cyclodextrin. 
     
     
         12 . A method as in  claim 2 , wherein said diffusion enhancing compound is TSC. 
     
     
         13 . A method as in  claim 2 , wherein said thrombolytic agent is selected from the group consisting of tPA, reteplase, tenecteplase, anistreplase, streptokinase, and urokinase. 
     
     
         14 . A method as in  claim 2 , wherein said thrombolytic agent is tPA. 
     
     
         15 . A method as in  claim 2 , wherein the diffusion enhancing compound is administered within 4 hours of the onset of symptoms and the thrombolytic agent is administered within 12 hours of the onset of symptoms. 
     
     
         16 . A method as in  claim 2 , wherein the diffusion enhancing compound is administered within 3 hours of the onset of symptoms and the thrombolytic agent is administered within 9 hours of the onset of symptoms. 
     
     
         17 - 18 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.